(Q)-Twist analysis of trastuzumab plus fluoropyrimidine/cisplatin (T-XP/FP) versus XP/FP alone as first-line therapy for advanced HER2-positive gastric cancer

被引：0
|
作者：
Chung, H. C.
Bang, Y.
Van Cutsem, E.
Kang, Y.
Hamamoto, Y.
Moiseyenko, V.
Gotovkin, E.
Urspruch, A.
Ducournau, P.
机构：
[1] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Seoul, South Korea
[2] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea
[3] Univ Hosp Gasthuisberg, Dept Digest Oncol, B-3000 Louvain, Belgium
[4] Univ Ulsan Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[5] Tochigi Canc Ctr, Utsunomiya, Tochigi, Japan
[6] Inst Oncol, Dept Biotherapy & BMT, St Petersburg, Russia
[7] Ivanovo Reg Oncol Dispensary, Ivanovo, Russia
[8] F Hoffmann La Roche, Basel, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4048
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A randomized phase 2 study of HLX22 plus trastuzumab biosimilar HLX02 and XELOX as first-line therapy for HER2-positive advanced gastric cancer
    Li, Ning
    Qiu, Meng
    Zhang, Yanqiao
    Yang, Mudan
    Lu, Linzhi
    Li, Wei
    Ma, Yuntao
    Hou, Xiaoming
    Sun, Guoping
    Cai, Mingquan
    Wang, Jingran
    Lu, Jianwei
    Zhong, Diansheng
    Huo, Zhibin
    Zhang, Jingdong
    Yin, Xianli
    Deng, Jun
    Liu, Zimin
    Pan, Hongming
    Chen, Ye
    Yang, Futang
    Yu, Haoyu
    Li, Jing
    Wang, Qingyu
    Zhu, Jun
    Li, Jin
    MED, 2024, 5 (10):
  • [22] Maintenance therapy with trastuzumab plus /- fluoropyrimidine in non-progressive HER-2 positive advanced gastroesophageal cancer patients after first-line chemotherapy.
    Lopez, Anthony
    Chen, Hsiang-Chun
    Harada, Kazuto
    Murphy, Mariela A. Blum
    Rogers, Jane Elizabeth
    Thomas, Irene
    Amlashi, Fatemeh Ghazanfari
    Ajani, Jaffer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] Trastuzumab plus chemotherapy versus chemotherapy alone in HER2-positive gastric cancer treatment in Iran: a cost-effectiveness analysis
    Kaveh, Sara
    Ghadimi, Nashmil
    Alvar, Amirhossein Zarei
    Roudini, Kamran
    Daroudi, Rajabali
    HEALTH ECONOMICS REVIEW, 2024, 14 (01):
  • [24] A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer
    Choong-kun Lee
    Sun Young Rha
    Hyo Song Kim
    Minkyu Jung
    Beodeul Kang
    Jingmin Che
    Woo Sun Kwon
    Sejung Park
    Woo Kyun Bae
    Dong-Hoe Koo
    Su-Jin Shin
    Hyunki Kim
    Hei-Cheul Jeung
    Dae Young Zang
    Sang Kil Lee
    Chung Mo Nam
    Hyun Cheol Chung
    Nature Communications, 13
  • [25] A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer
    Lee, Choong-kun
    Rha, Sun Young
    Kim, Hyo Song
    Jung, Minkyu
    Kang, Beodeul
    Che, Jingmin
    Kwon, Woo Sun
    Park, Sejung
    Bae, Woo Kyun
    Koo, Dong-Hoe
    Shin, Su-Jin
    Kim, Hyunki
    Jeung, Hei-Cheul
    Zang, Dae Young
    Lee, Sang Kil
    Nam, Chung Mo
    Chung, Hyun Cheol
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [26] Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy
    Kadowaki, Shigenori
    Masuishi, Toshiki
    Eto, Tetsuya
    Narita, Yukiya
    Taniguchi, Hiroya
    Ura, Takashi
    Ando, Masashi
    Tajika, Masahiro
    Niwa, Yasumasa
    Yatabe, Yasushi
    Muro, Kei
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (04) : 807 - 813
  • [27] Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy
    Shigenori Kadowaki
    Toshiki Masuishi
    Tetsuya Eto
    Yukiya Narita
    Hiroya Taniguchi
    Takashi Ura
    Masashi Ando
    Masahiro Tajika
    Yasumasa Niwa
    Yasushi Yatabe
    Kei Muro
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 807 - 813
  • [28] Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer
    Taroh Satoh
    Yasushi Omuro
    Yasutsuna Sasaki
    Yasuo Hamamoto
    Narikazu Boku
    Takao Tamura
    Atsushi Ohtsu
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 949 - 955
  • [29] Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer
    Satoh, Taroh
    Omuro, Yasushi
    Sasaki, Yasutsuna
    Hamamoto, Yasuo
    Boku, Narikazu
    Tamura, Takao
    Ohtsu, Atsushi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (04) : 949 - 955
  • [30] Sunitinib plus docetaxel and trastuzumab as first-line therapy for HER2+advanced breast cancer
    Cardoso, F.
    Canon, J. L.
    Amadori, D.
    Dirix, L.
    Villa, E.
    Aldrighetti, D.
    Machiels, J. P.
    Verkh, L.
    Kern, K.
    Giorgetti, C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 283 - 283
12345